Cancer Discovery

Poliovirus therapy for recurrent glioblastoma has three year survival rate of 21 percent

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment. Phase 1 clinical trial results of the poliovirus
Cancer Discovery

Is anti-angiogenic therapy to treat glioblastomas a viable option?

Results of two phase 2 clinical trials testing cabozantinib suggest that anti-angiogenic therapy could be used to treat glioblastomas Glioblastoma is an aggressive type of brain tumor that affects approximately 74,000 individuals across the world, annually. The current standard of treatment for this tumour type consists of surgical removal of the tumor, accompanied with radiation therapy and chemotherapy. Despite patients undergoing a rigorous treatment regimen, the rate of tumor recurrence
Biotechnology cancer Immunotherapies rare diseases

Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy

A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology. The altered adenovirus, called Delta-24-RGD or DNX-2401, was injected one time directly into the tumors of 25
Biotechnology

Combination Treatment Targeting Glucose in Advanced Brain Cancer Shows Promising Results in Preclinical Study

UCLA scientists have discovered a potential combination treatment for glioblastoma, the deadliest form of brain cancer in adults. The three-year study led by Dr. David Nathanson, a member of UCLA's Jonsson Comprehensive Cancer Center, found that the drug combination tested in mice disrupts and exploits glucose intake, essentially cutting off the tumor's nutrients and energy supply. This treatment then stimulates cell death pathways—which control the cancer cells' fate—and prevents the
Cancer Discovery

Study Suggests that Zika Virus Could Be Used to Treat Brain Cancer Patients

Recent outbreaks of Zika virus have revealed that the virus causes brain defects in unborn children. But in a study to be published September 5 in The Journal of Experimental Medicine, researchers from Washington University School of Medicine in St. Louis and the University of California, San Diego report that the virus could eventually be used to target and kill cancer cells in the brain. Glioblastoma is the most common
Biotechnology

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed

A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke Cancer Institute report. Patients treated with the study drug (dose-intensified temozolomide and vaccines) were continuously monitored for toxicity and adverse events. Study patients experienced known side effects with temozolomide, including